BURULIVAC

Identification and development of vaccine candidates for Buruli Ulcer Disease

 Coordinatore BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN 

 Organization address address: BERNHARD NOCHT STRASSE 74
city: HAMBURG
postcode: 20359

contact info
Titolo: Ms.
Nome: Susanne
Cognome: Crohn
Email: send email
Telefono: +49 40 428 18 611
Fax: +49 40 42 79 48 535

 Nazionalità Coordinatore Germany [DE]
 Sito del progetto http://www.burulivac.eu/
 Totale costo 6˙021˙315 €
 EC contributo 4˙599˙983 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2009-single-stage
 Funding Scheme CP-FP-SICA
 Anno di inizio 2010
 Periodo (anno-mese-giorno) 2010-03-01   -   2013-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN

 Organization address address: BERNHARD NOCHT STRASSE 74
city: HAMBURG
postcode: 20359

contact info
Titolo: Ms.
Nome: Susanne
Cognome: Crohn
Email: send email
Telefono: +49 40 428 18 611
Fax: +49 40 42 79 48 535

DE (HAMBURG) coordinator 438˙413.00
2    SCHWEIZERISCHES TROPEN- UND PUBLIC HEALTH-INSTITUT

 Organization address address: SOCINSTRASSE 57
city: Basel
postcode: CH-4002

contact info
Titolo: Mr.
Nome: Stefan
Cognome: Mörgeli
Email: send email
Telefono: +41 61 284 83 20
Fax: +41 61 284 81 01

CH (Basel) participant 465˙383.00
3    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

 Organization address address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539

contact info
Titolo: Dr.
Nome: Gisela
Cognome: Bretzel
Email: send email
Telefono: +49 89 2180 3618
Fax: +49 89 336112

DE (MUENCHEN) participant 398˙392.00
4    INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE

 Organization address address: Rue Juliette Wytsman 14
city: BRUXELLES
postcode: 1050

contact info
Titolo: Ms.
Nome: Hilde
Cognome: Millaire
Email: send email
Telefono: +32 2 642 5111
Fax: +32 2 642 5001

BE (BRUXELLES) participant 395˙420.00
5    INSTITUT PASTEUR

 Organization address address: RUE DU DOCTEUR ROUX 25-28
city: PARIS CEDEX 15
postcode: 75724

contact info
Titolo: Dr.
Nome: Nadia
Cognome: Khelef
Email: send email
Telefono: +33 1 40 61 33 78
Fax: +33 1 40 61 39 40

FR (PARIS CEDEX 15) participant 384˙592.00
6    Kwame Nkrumah University of Science and Technology

 Organization address address: "Private Mail Bag, University Post Office"
city: Kumasi
postcode: Ash

contact info
Titolo: Prof.
Nome: Kwabena Antwi
Cognome: Danso
Email: send email
Telefono: 2335160303
Fax: 2335160302

GH (Kumasi) participant 368˙576.00
7    PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE

 Organization address address: Nationalestraat 155
city: ANTWERPEN
postcode: 2000

contact info
Titolo: Mr.
Nome: Jef
Cognome: Van Lint
Email: send email
Telefono: +32 3 2476486
Fax: +32 3 2476223

BE (ANTWERPEN) participant 326˙130.00
8    EUROPEAN RESEARCH AND PROJECT OFFICE GMBH

 Organization address address: Science Park 1, Stuhlsatzenhausweg 69
city: SAARBRUECKEN
postcode: 66123

contact info
Titolo: Dr.
Nome: Vera
Cognome: Siegmund
Email: send email
Telefono: +49 681 959 23385
Fax: +49 681 959 23370

DE (SAARBRUECKEN) participant 313˙400.00
9    LIONEX GMBH

 Organization address address: Salzdahlumer Strasse 196
city: BRAUNSCHWEIG
postcode: 38126

contact info
Titolo: Prof.
Nome: Mahavir
Cognome: Singh
Email: send email
Telefono: +49 531 260 12 66
Fax: +49 531 260 11 59

DE (BRAUNSCHWEIG) participant 263˙225.00
10    INSTITUT MEDICAL EVANGELIQUE DE KIMPESE

 Organization address address: Matadi Road IME/Kimpese Hospital
city: Kimpese

contact info
Titolo: Ms.
Nome: Virginie
Cognome: Basilua Nzuzi
Email: send email
Telefono: 243815000000

CD (Kimpese) participant 257˙470.00
11    UNIVERSIDADE DO MINHO

 Organization address address: Largo do Paco
city: BRAGA
postcode: 4704553

contact info
Titolo: Prof.
Nome: Rui Manuel Costa
Cognome: Vieira De Castro
Email: send email
Telefono: +351 253 601192
Fax: +351 253 601198

PT (BRAGA) participant 232˙344.00
12    DEUTSCHES LEPRA- UND TUBERKULOSEHILFE EV

 Organization address address: MARIANNHILLSTRASSE 1C
city: WURZBURG
postcode: 97074

contact info
Titolo: Ms.
Nome: Carola
Cognome: Muehleisen
Email: send email
Telefono: +49 931 7948 116
Fax: +49 931 7948 160

DE (WURZBURG) participant 218˙306.00
13    Ministere de la sante

 Organization address address: n/a
city: Cotonou
postcode: 06 BP 3029

contact info
Titolo: Mr.
Nome: Affolabi Albert
Cognome: Fatolou
Email: send email
Telefono: 22997444905
Fax: 22921331827

BJ (Cotonou) participant 143˙131.00
14    CENTRE NATIONAL HOSPITALIER DE PNEUMO-PHTISIOLOGIE

 Organization address address: LAZARET AKPAKPA
city: COTONOU
postcode: 1

contact info
Titolo: Mr.
Nome: Koissi Pascal
Cognome: Mensah
Email: send email
Telefono: +229 21331533

BJ (COTONOU) participant 142˙729.00
15    ST GEORGE'S HOSPITAL MEDICAL SCHOOL

 Organization address address: Cranmer Terrace
city: LONDON
postcode: SW17 0RE

contact info
Titolo: Mr.
Nome: Paul
Cognome: Craven
Email: send email
Telefono: +44 208 725 5012
Fax: +44 208 725 0794

UK (LONDON) participant 131˙570.00
16    ACADEMISCH ZIEKENHUIS GRONINGEN

 Organization address address: Hanzeplein 1
city: GRONINGEN
postcode: 9713 GZ

contact info
Titolo: Ms.
Nome: Katinka
Cognome: Mulder
Email: send email
Telefono: +31 50 3611209
Fax: +31 50 3619320

NL (GRONINGEN) participant 120˙902.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

ulcer    treatment    buruli    african    immunity    endemic    disease    bud    immune    therapeutic    vaccine       prophylactic    mycolactone    clinical    protective    humans    bacterial    identification    neglected    caused    children    pathogenesis    capacity    respect    candidates    molecular    pre    ulcerans    mycobacterium    infection    bioinformatics    burulivac    countries    toxin   

 Obiettivo del progetto (Objective)

'Buruli ulcer disease (BUD), caused by Mycobacterium ulcerans, is a neglected bacterial infection of the poor in remote rural areas, mostly affecting children. BUD, the third most common mycobacterial disease in immunocompetent humans after tuberculosis and leprosy, is most endemic in West Africa, but cases have been reported from more than 30 countries. BUD is a mutilating disease leading to severe disability. Treatment with antibiotics is possible but is long-lasting and requires injections, shows treatment failures and drug resistance may occur. A vaccine against M. ulcerans would protect persons at risk in highly endemic areas and could be used as a therapeutic vaccine to shorten duration of treatment and to prevent relapses. The general objective of BuruliVac is to identify and develop novel vaccine candidates suitable for translation into clinical application. This objective will be achieved by a multidisciplinary approach involving among others basic and applied research in immunology, bioinformatics, molecular genetics, tropical medicine, microbiology and clinical bacteriology. As currently no existing vaccine lead candidate is available, the consortium will identify and develop new vaccine candidates of different types, will evaluate them using bioinformatics, applied genomics and proteomics and will subject them to consecutive test systems. For evaluation of vaccine candidates regarding their application in humans, the consortium will also study the immune response and disease immunopathology to define correlates of protection. Essential pre-clinical testing in vitro and in vivo will select a small number of candidates that is amenable to be introduced into clinical studies.'

Introduzione (Teaser)

Prophylactic or preventive vaccination has provided treatment solutions for many infectious diseases. Based on this, EU and African researchers joined forces to develop novel vaccine candidates against the neglected Buruli ulcer disease (BUD).

Descrizione progetto (Article)

BUD is a rare, poverty-related infection caused by Mycobacterium ulcerans that predominantly affects African children. Patients present with a progressive necrosis of skin, subcutaneous tissue and bone, but the transmission mode of BUD remains elusive.

Scientists on the EU-funded 'Identification and development of vaccine candidates for Buruli Ulcer Disease' (http://www.burulivac.eu (BURULIVAC)) project wished to investigate BUD pathogenesis and immunity mechanisms as well as develop novel therapeutic tools. Central to the project work was the capacity development of partner African institutions with respect to immunological analyses, treatment and disease management.

Among the key findings of the project were the pathophysiological impact of the bacterial mycolactone toxin and the identification of its molecular targets. Using a combination of biochemical assays, cellular imaging and animal models, researchers found that mycolactone interferes with the cell structure by altering its cytoskeleton. Upon infection, this damages the integrity of the epidermis and is responsible for BUD pathogenesis.

Characterisation of patient immune responses indicated that infected individuals have an overall suppressed immune system with reduced levels of multiple chemokines, cytokines and immunoglobulins. This profile was associated with an infection-associated drop of glycolytic and oxidative metabolism.

With respect to therapy, BURULIVAC performed extensive work towards the development of prophylactic vaccines. Live bacteria lacking the mycolactone toxin proved very effective at generating protective immunity against virulent strains of M.ulcerans. Partners also generated monoclonal antibodies against mycolactone, following a careful screening and pre-selection process of candidates for their protective capacity in a mouse model.

Overall, the BURULIVAC study has increased awareness about BUD and raised the infrastructure and technological capacity in affected countries. The commercial development of a lead vaccine against BUD will no doubt provide novel prevention and therapeutic options against this debilitating disease.

Altri progetti dello stesso programma (FP7-HEALTH)

HEMIBIO (2011)

HEPATIC MICROFLUIDIC BIOREACTOR

Read More  

PATIENTPARTNER (2008)

Identifying the Needs for Patients Partnering in Clinical Research

Read More  

HERMIONE-2MAN (2013)

First in Man Novel Anticancer Therapeutic based on Dependence Receptors Concept

Read More